BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo cocktail shows promise for pancreatic cancer patients before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline remova…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New chemo cocktail aims to boost pancreatic cancer surgery success
Disease control Recruiting nowThis phase 2 trial is testing a chemotherapy combination called NALIRIFOX given before surgery to people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough to allow successful removal and reduce the chance of the cancer coming back. The study wil…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Pulsed proton beams aim to tame tough pancreatic tumors
Disease control Recruiting nowThis phase II trial tests a new radiation technique called PULSAR, which delivers short, powerful proton beam pulses every few weeks, adapted to tumor changes. It is for people with locally advanced or limited metastatic pancreatic cancer who have already had some chemotherapy. T…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Pancreatic cancer drugs put to the test in early trial
Knowledge-focused Recruiting nowThis early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Genetic blueprint may unlock better pancreatic cancer care
Knowledge-focused Recruiting nowThis study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC